Entresto's primary patent is set to expire in November 2025 [1]. This date marks a significant point for the drug, as it generally permits generic manufacturers to enter the market [1].
When can generic Entresto be launched?
Following the expiration of Entresto's primary patent in November 2025, generic versions of the drug could become available. The actual launch timing can depend on several factors, including regulatory approvals for generic versions and any ongoing legal challenges or settlements [1][2].
What is Entresto and what is it used for?
Entresto, also known by its generic name sacubitril/valsartan, is a medication prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with symptomatic chronic heart failure with reduced ejection fraction [3]. It is a combination of a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (valsartan) [3].
How does Entresto work?
Entresto functions by enhancing the body's natriuretic peptide system. Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides. Increased levels of these peptides promote vasodilation, natriuresis (sodium excretion), and diuresis (urine production), which can lower blood pressure and reduce the workload on the heart. Valsartan blocks the effects of angiotensin II, a hormone that constricts blood vessels and stimulates salt and water retention [3].
Are there other patents protecting Entresto?
Beyond the primary patent expiring in November 2025, Novartis, the manufacturer of Entresto, may hold other patents related to different aspects of the drug, such as manufacturing processes, specific formulations, or method of use patents [1][2]. These secondary patents could potentially extend market exclusivity for certain applications or forms of the drug even after the main patent expires. DrugPatentWatch.com tracks these patent landscapes [1].
What is the significance of Entresto's patent expiration for patients?
The expiration of Entresto's patent is expected to lead to the availability of generic versions. Generic drugs are typically manufactured to be bioequivalent to their brand-name counterparts but are often sold at a lower cost. This could significantly reduce the financial burden for patients and healthcare systems, potentially increasing access to this important heart failure treatment [1][2].
What are the potential challenges to Entresto's patent expiration?
While the primary patent expiration date is set for November 2025, patent litigation is common in the pharmaceutical industry. Generic manufacturers may challenge existing patents, or the brand-name manufacturer might file lawsuits to prevent generic entry. Settlements or court decisions in these cases can alter the timeline for generic availability [1][2].
How does Entresto compare to other heart failure treatments?
Entresto has demonstrated significant benefits in clinical trials, notably the PARADIGM-HF study, which showed a substantial reduction in cardiovascular death and heart failure hospitalizations compared to an ACE inhibitor (enalapril) [3]. Its mechanism of action, combining neprilysin inhibition with angiotensin receptor blockade, differentiates it from other heart failure therapies that primarily target the renin-angiotensin-aldosterone system or work as beta-blockers or mineralocorticoid receptor antagonists [3].
Who manufactures Entresto?
Entresto is manufactured by Novartis [3].
Sources:
[1] DrugPatentWatch.com
[2] Various pharmaceutical news and analysis sites
[3] Novartis Pharmaceuticals